Clinical trials
Churg-Strauss Syndrome trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 4 |
| Completed | 4 |
| Unknown status | 4 |
| Recruiting | 2 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 3 |
| AstraZeneca | 2 |
| Imperial College London | 2 |
| University of Oxford | 2 |
| Charite University, Berlin, Germany | 1 |
| Guy's and St Thomas' NHS Foundation Trust | 1 |
| NS Pharma, Inc. | 1 |
| Portsmouth Hospitals NHS Trust | 1 |
| Queen Mary University of London | 1 |
| University of British Columbia | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Churg-Strauss Syndrome | 16 |
| Granulomatosis with Polyangiitis | 6 |
| Microscopic Polyangiitis | 6 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 4 |
| Polyarteritis Nodosa | 2 |
| Systemic Vasculitis | 2 |
| Takayasu Arteritis | 2 |
| Vasculitis | 2 |
| Asthma | 1 |
| Eosinophilic Esophagitis | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.